sentence1
stringlengths 35
423
| sentence2
stringlengths 34
427
| score
int64 -1
1
|
|---|---|---|
There is very low-quality evidence that treatment with iStent may result in higher proportions of participants who are drop-free or achieving better IOP control, in the short, medium, or long-term. | There is very low-quality evidence that treatment with iStent may result in lower proportions of participants who are drop-free or achieving worse IOP control, in the short, medium, or long-term. | -1 |
There is very low-quality evidence that treatment with iStent may result in higher proportions of participants who are drop-free or achieving better IOP control, in the short, medium, or long-term. | There is no evidence that treatment with iStent results in higher proportions of participants who are drop-free or achieving better IOP control, in the short, medium, or long-term. | 0 |
There is very low-quality evidence that treatment with iStent may result in higher proportions of participants who are drop-free or achieving better IOP control, in the short, medium, or long-term. | There is evidence that treatment with iStent results in higher proportions of participants who are drop-free or achieving better IOP control, in the short, medium, or long-term. | 1 |
According to data available, travoprost is more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. | According to data available, travoprost is not more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. | -1 |
According to data available, travoprost is more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. | According to data available, travoprost is less effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. | -1 |
According to data available, travoprost is more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. | There is no evidence that travoprost is more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. | 0 |
According to data available, travoprost is more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. | According to data available, travoprost may be more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. | 1 |
Compared with other prostaglandin analogues, travoprost appears to be equivalent to bimatoprost and latanoprost. | Compared with other prostaglandin analogues, travoprost does not appear to be equivalent to bimatoprost and latanoprost. | -1 |
Compared with other prostaglandin analogues, travoprost appears to be equivalent to bimatoprost and latanoprost. | There is no evidence that, compared with other prostaglandin analogues, travoprost appears to be equivalent to bimatoprost and latanoprost. | 0 |
Compared with other prostaglandin analogues, travoprost appears to be equivalent to bimatoprost and latanoprost. | Compared with other prostaglandin analogues, travoprost is equivalent to bimatoprost and latanoprost. | 1 |
Although a limited number of local side-effects were reported, no serious treatment-related side-effects were reported. | Although a limited number of local side-effects were reported, serious treatment-related side-effects were reported. | -1 |
Although a limited number of local side-effects were reported, no serious treatment-related side-effects were reported. | Although a limited number of local side-effects were reported, there is no evidence that no serious treatment-related side-effects were reported. | 0 |
NPFSI was associated with equivalent efficacy to standard NPFS in lowering IOP. | NPFSI was not associated with equivalent efficacy to standard NPFS in lowering IOP. | -1 |
NPFSI was associated with equivalent efficacy to standard NPFS in lowering IOP. | There is no evidence that NPFSI was associated with equivalent efficacy to standard NPFS in lowering IOP. | 0 |
NPFSI was associated with equivalent efficacy to standard NPFS in lowering IOP. | NPFSI may be associated with equivalent efficacy to standard NPFS in lowering IOP. | 1 |
Comparable proportions of patients reached the IOP target with NPFSI and NPFS. | Comparable proportions of patients did not reach the IOP target with NPFSI and NPFS. | -1 |
Comparable proportions of patients reached the IOP target with NPFSI and NPFS. | Different proportions of patients reached the IOP target with NPFSI and NPFS. | -1 |
Comparable proportions of patients reached the IOP target with NPFSI and NPFS. | There is no evidence that comparable proportions of patients reached the IOP target with NPFSI and NPFS. | 0 |
Both surgeries were well tolerated. | Both surgeries were not well tolerated. | -1 |
Both surgeries were well tolerated. | There is no evidence that both surgeries were well tolerated. | 0 |
Both surgeries were well tolerated. | Both surgeries may be well tolerated. | 1 |
These results demonstrated that statin use was protective for early and exudative AMD. | These results demonstrated that statin use was not protective for early and exudative AMD. | -1 |
These results demonstrated that statin use was protective for early and exudative AMD. | These results demonstrated that statin use was a risk factor for early and exudative AMD. | -1 |
These results demonstrated that statin use was protective for early and exudative AMD. | There is no evidence that statin use was protective for early and exudative AMD. | 0 |
These results demonstrated that statin use was protective for early and exudative AMD. | These results demonstrated that statin use might be protective for early and exudative AMD. | 1 |
Lipid-lowering agents, including statins, do not appear to lower the risk of developing AMD, although clinically significant effects cannot be excluded. | Lipid-lowering agents, including statins, appear to lower the risk of developing AMD, although clinically significant effects cannot be excluded. | -1 |
Lipid-lowering agents, including statins, do not appear to lower the risk of developing AMD, although clinically significant effects cannot be excluded. | Lipid-lowering agents, including statins, do not appear to increase the risk of developing AMD, although clinically significant effects cannot be excluded. | -1 |
Lipid-lowering agents, including statins, do not appear to lower the risk of developing AMD, although clinically significant effects cannot be excluded. | There is no evidence that lipid-lowering agents, including statins, appear to lower the risk of developing AMD, although clinically significant effects cannot be excluded. | 0 |
Heavy alcohol consumption (more than three standard drinks per day) is associated with an increased risk of early AMD. | Heavy alcohol consumption (more than three standard drinks per day) is not associated with an increased risk of early AMD. | -1 |
Heavy alcohol consumption (more than three standard drinks per day) is associated with an increased risk of early AMD. | Heavy alcohol consumption (more than three standard drinks per day) is associated with a reduced risk of early AMD. | -1 |
Heavy alcohol consumption (more than three standard drinks per day) is associated with an increased risk of early AMD. | There is no evidence that heavy alcohol consumption (more than three standard drinks per day) is associated with an increased risk of early AMD. | 0 |
Heavy alcohol consumption (more than three standard drinks per day) is associated with an increased risk of early AMD. | Heavy alcohol consumption (more than three standard drinks per day) may be associated with an increased risk of early AMD. | 1 |
The LIPC rs493258 polymorphism showed a significant association with a lower risk of AMD under the allelic model (OR = 0.87, 95% CI = 0.84-0.90). | The LIPC rs493258 polymorphism did not show a significant association with a lower risk of AMD under the allelic model (OR = 0.87, 95% CI = 0.84-0.90). | -1 |
The LIPC rs493258 polymorphism showed a significant association with a lower risk of AMD under the allelic model (OR = 0.87, 95% CI = 0.84-0.90). | The LIPC rs493258 polymorphism showed a significant association with a higher risk of AMD under the allelic model (OR = 0.87, 95% CI = 0.84-0.90). | -1 |
A rigorous analysis shows a weak but statistically significant association between aspirin use and the risk of AMD; a result which is different to that previously reported. | A rigorous analysis shows a weak and not statistically significant association between aspirin use and the risk of AMD; a result which is different to that previously reported. | -1 |
A rigorous analysis shows a weak but statistically significant association between aspirin use and the risk of AMD; a result which is different to that previously reported. | A rigorous analysis shows a strong statistically significant association between aspirin use and the risk of AMD; a result which is different to that previously reported. | 1 |
Furthermore, there is no evidence to suggest a superiority of vitrectomy over laser in terms of functional outcomes. | Furthermore, there is no evidence to suggest an inferiority of vitrectomy over laser in terms of functional outcomes. | -1 |
Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. | Compared with timolol, latanoprost was not significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. | -1 |
Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. | Compared with timolol, latanoprost was significantly less effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. | -1 |
Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. | Compared with timolol, latanoprost might be significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. | 1 |
Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. | Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but not lower risk of systemic adverse events, and might be a good substitute for CACG patients. | -1 |
Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. | Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects and higher risk of systemic adverse events, and might be a good substitute for CACG patients. | -1 |
There is no evidence from good quality randomized trials or non-randomized studies of the effectiveness of lens extraction for chronic primary angle-closure glaucoma. | There is evidence from good quality randomized trials or non-randomized studies of the effectiveness of lens extraction for chronic primary angle-closure glaucoma. | -1 |
There is no evidence from good quality randomized trials or non-randomized studies of the effectiveness of lens extraction for chronic primary angle-closure glaucoma. | There is evidence from good quality randomized trials or non-randomized studies of the effectiveness of lens extraction for chronic primary angle-closure glaucoma. | 0 |
The present meta-analysis indicated that the ε4/ε4 genotype is associated with increased risk of POAG in Asians. | The present meta-analysis indicated that the ε4/ε4 genotype is not associated with increased risk of POAG in Asians. | -1 |
The present meta-analysis indicated that the ε4/ε4 genotype is associated with increased risk of POAG in Asians. | The present meta-analysis indicated that the ε4/ε4 genotype is associated with decreased risk of POAG in Asians. | -1 |
The present meta-analysis indicated that the ε4/ε4 genotype is associated with increased risk of POAG in Asians. | There is no evidence that the ε4/ε4 genotype is associated with increased risk of POAG in Asians. | 0 |
The present meta-analysis indicated that the ε4/ε4 genotype is associated with increased risk of POAG in Asians. | The present meta-analysis indicated that the ε4/ε4 genotype might be associated with increased risk of POAG in Asians. | 1 |
This review suggests that CPLRADs may facilitate direct clinical decision making for glaucoma diagnosis and evaluation, and may provide a deeper understanding of the pathomechanism of glaucoma. | This review suggests that CPLRADs may not facilitate direct clinical decision making for glaucoma diagnosis and evaluation, and may provide a deeper understanding of the pathomechanism of glaucoma. | -1 |
This review suggests that CPLRADs may facilitate direct clinical decision making for glaucoma diagnosis and evaluation, and may provide a deeper understanding of the pathomechanism of glaucoma. | There is no evidence that CPLRADs facilitate direct clinical decision making for glaucoma diagnosis and evaluation, and may provide a deeper understanding of the pathomechanism of glaucoma. | 0 |
This review suggests that CPLRADs may facilitate direct clinical decision making for glaucoma diagnosis and evaluation, and may provide a deeper understanding of the pathomechanism of glaucoma. | This review suggests that CPLRADs facilitate direct clinical decision making for glaucoma diagnosis and evaluation, and may provide a deeper understanding of the pathomechanism of glaucoma. | 1 |
Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small increase in risk of future CVD, subgroup analyses limited to prospective studies demonstrate a markedly increased risk of CVD among people with late AMD. | Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small increase in risk of future CVD, subgroup analyses limited to prospective studies did not demonstrate a markedly increased risk of CVD among people with late AMD. | -1 |
Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small increase in risk of future CVD, subgroup analyses limited to prospective studies demonstrate a markedly increased risk of CVD among people with late AMD. | Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small increase in risk of future CVD, subgroup analyses limited to prospective studies demonstrate a markedly decreased risk of CVD among people with late AMD. | -1 |
Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small increase in risk of future CVD, subgroup analyses limited to prospective studies demonstrate a markedly increased risk of CVD among people with late AMD. | Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small increase in risk of future CVD, subgroup analyses limited to prospective studies demonstrate an increased risk of CVD among people with late AMD. | 1 |
Based on current research, low-vision rehabilitation aids improve reading speed. | Based on current research, low-vision rehabilitation aids do not improve reading speed. | -1 |
Based on current research, low-vision rehabilitation aids improve reading speed. | Based on current research, low-vision rehabilitation aids decrease reading speed. | -1 |
Based on current research, low-vision rehabilitation aids improve reading speed. | There is no evidence that low-vision rehabilitation aids improve reading speed. | 0 |
Based on current research, low-vision rehabilitation aids improve reading speed. | Based on current research, low-vision rehabilitation aids may improve reading speed. | 1 |
However, they do not have a significant effect on depression scores in those 55 and older with AMD. | However, they have a significant effect on depression scores in those 55 and older with AMD. | -1 |
However, they do not have a significant effect on depression scores in those 55 and older with AMD. | However, there is no evidence that they have a significant effect on depression scores in those 55 and older with AMD. | 0 |
However, they do not have a significant effect on depression scores in those 55 and older with AMD. | However, they may not have a significant effect on depression scores in those 55 and older with AMD. | 1 |
The meta-analysis shows that both treatments are comparably safe. However, the findings from our study must be confirmed in future research via well-designed cohort or intervention studies because of the limited number of studies. | The meta-analysis shows that both treatments are comparably not safe. However, the findings from our study must be confirmed in future research via well-designed cohort or intervention studies because of the limited number of studies. | -1 |
The meta-analysis shows that both treatments are comparably safe. However, the findings from our study must be confirmed in future research via well-designed cohort or intervention studies because of the limited number of studies. | The meta-analysis shows that both treatments are comparably unsafe. However, the findings from our study must be confirmed in future research via well-designed cohort or intervention studies because of the limited number of studies. | -1 |
The IVB group was associated with numerically greater but nonsignificant IOP lowering efficacy compared with the control group (P=0.152). | The IVB group was associated with numerically lower but nonsignificant IOP lowering efficacy compared with the control group (P=0.152). | -1 |
The IVB group was associated with significant greater complete success rates compared with the control group, with a pooled OR of 3.18 (1.41 to 7.19). | The IVB group was associated with significant lower complete success rates compared with the control group, with a pooled OR of 3.18 (1.41 to 7.19). | -1 |
The IVB group was associated with a significantly lower frequency of hyphema than the control group, with a pooled OR of 0.15 (0.07 to 0.32). | The IVB group was associated with a significantly higher frequency of hyphema than the control group, with a pooled OR of 0.15 (0.07 to 0.32). | -1 |
This meta-analysis suggests that latanoprost is more effective than timolol in lowering IOP. | This meta-analysis suggests that latanoprost is not more effective than timolol in lowering IOP. | -1 |
This meta-analysis suggests that latanoprost is more effective than timolol in lowering IOP. | This meta-analysis suggests that latanoprost is less effective than timolol in lowering IOP. | -1 |
This meta-analysis suggests that latanoprost is more effective than timolol in lowering IOP. | There is no evidence that latanoprost is more effective than timolol in lowering IOP. | 0 |
This meta-analysis suggests that latanoprost is more effective than timolol in lowering IOP. | This meta-analysis suggests that latanoprost may be more effective than timolol in lowering IOP. | 1 |
However, latanoprost caused iris pigmentation in more patients than timolol (relative risk = 8.01, 95% confidence intervals 1.87, 34.30). | However, latanoprost did not cause iris pigmentation in more patients than timolol (relative risk = 8.01, 95% confidence intervals 1.87, 34.30). | -1 |
However, latanoprost caused iris pigmentation in more patients than timolol (relative risk = 8.01, 95% confidence intervals 1.87, 34.30). | However, latanoprost caused iris pigmentation in less patients than timolol (relative risk = 8.01, 95% confidence intervals 1.87, 34.30). | -1 |
However, latanoprost caused iris pigmentation in more patients than timolol (relative risk = 8.01, 95% confidence intervals 1.87, 34.30). | There is no evidence that latanoprost caused iris pigmentation in more patients than timolol (relative risk = 8.01, 95% confidence intervals 1.87, 34.30). | 0 |
Our meta-analysis provides strong evidence that the APOE ε2/ε3/ε4 polymorphism is not associated with POAG susceptibility in any populations. | Our meta-analysis provides strong evidence that the APOE ε2/ε3/ε4 polymorphism is associated with POAG susceptibility in all populations. | -1 |
Our meta-analysis provides strong evidence that the APOE ε2/ε3/ε4 polymorphism is not associated with POAG susceptibility in any populations. | There is no evidence that the APOE ε2/ε3/ε4 polymorphism is associated with POAG susceptibility in any populations. | 0 |
Our meta-analysis provides strong evidence that the APOE ε2/ε3/ε4 polymorphism is not associated with POAG susceptibility in any populations. | Our meta-analysis provides evidence that the APOE ε2/ε3/ε4 polymorphism is not associated with POAG susceptibility in any populations. | 1 |
Outreach screening is an effective alternative to on-site specialist examination. It has potential to increase screening coverage of high-risk patients with DR in remote and resource-poor settings without the risk of missing DR and the opportunity to prevent vision loss. | Outreach screening is not an effective alternative to on-site specialist examination. It does not have potential to increase screening coverage of high-risk patients with DR in remote and resource-poor settings without the risk of missing DR and the opportunity to prevent vision loss. | -1 |
Outreach screening is an effective alternative to on-site specialist examination. It has potential to increase screening coverage of high-risk patients with DR in remote and resource-poor settings without the risk of missing DR and the opportunity to prevent vision loss. | Outreach screening is an ineffective alternative to on-site specialist examination. It has potential to decrease screening coverage of high-risk patients with DR in remote and resource-poor settings without the risk of missing DR and the opportunity to prevent vision loss. | -1 |
Outreach screening is an effective alternative to on-site specialist examination. It has potential to increase screening coverage of high-risk patients with DR in remote and resource-poor settings without the risk of missing DR and the opportunity to prevent vision loss. | Outreach screening may be an effective alternative to on-site specialist examination. It has potential to increase screening coverage of high-risk patients with DR in remote and resource-poor settings without the risk of missing DR and the opportunity to prevent vision loss. | 1 |
Our meta-analysis results suggest that diabetic patients are at significantly increased risk of developing primary open-angle glaucoma. | Our meta-analysis results suggest that diabetic patients are not at significantly increased risk of developing primary open-angle glaucoma. | -1 |
Our meta-analysis results suggest that diabetic patients are at significantly increased risk of developing primary open-angle glaucoma. | Our meta-analysis results suggest that diabetic patients are at significantly decreased risk of developing primary open-angle glaucoma. | -1 |
Our meta-analysis results suggest that diabetic patients are at significantly increased risk of developing primary open-angle glaucoma. | There is no evidence that diabetic patients are at significantly increased risk of developing primary open-angle glaucoma. | 0 |
Our meta-analysis results suggest that diabetic patients are at significantly increased risk of developing primary open-angle glaucoma. | Our meta-analysis results suggest that diabetic patients may be at significantly increased risk of developing primary open-angle glaucoma. | 1 |
In conclusion, the present meta-analysis suggested that GSTM1 null genotypes are associated with increased POAG risk in Asian populations but not in Caucasian and mixed populations. | In conclusion, the present meta-analysis suggested that GSTM1 null genotypes are associated with decreased POAG risk in Asian populations but not in Caucasian and mixed populations. | -1 |
In conclusion, the present meta-analysis suggested that GSTM1 null genotypes are associated with increased POAG risk in Asian populations but not in Caucasian and mixed populations. | In conclusion, the present meta-analysis suggested that GSTM1 null genotypes may be associated with increased POAG risk in Asian populations but not in Caucasian and mixed populations. | 1 |
Refractive error is associated with early AMD but not with late AMD. | There is no evidence that refractive error is associated with early AMD but not with late AMD. | 0 |
Refractive error is associated with early AMD but not with late AMD. | Refractive error may be associated with early AMD but not with late AMD. | 1 |
Refractive error is associated with early AMD but not with late AMD. | There is no evidence that refractive error is associated with early AMD but not with late AMD. | 0 |
Refractive error is associated with early AMD but not with late AMD. | Refractive error may be associated with early AMD but not with late AMD. | 1 |
Although the review found increased risk of open-angle glaucoma with pars plana vitrectomy, the studies were heterogenous or inconsistent regarding ocular hypertension and intraocular pressure increase. | Although the review found no increased risk of open-angle glaucoma with pars plana vitrectomy, the studies were heterogenous or inconsistent regarding ocular hypertension and intraocular pressure increase. | -1 |
Although the review found increased risk of open-angle glaucoma with pars plana vitrectomy, the studies were heterogenous or inconsistent regarding ocular hypertension and intraocular pressure increase. | Although the review found decreased risk of open-angle glaucoma with pars plana vitrectomy, the studies were heterogenous or inconsistent regarding ocular hypertension and intraocular pressure increase. | -1 |
Refractive error is associated with AMD, although a temporal relationship cannot be determined on the basis of current evidence. | Refractive error is not associated with AMD, although a temporal relationship cannot be determined on the basis of current evidence. | -1 |
Refractive error is associated with AMD, although a temporal relationship cannot be determined on the basis of current evidence. | Refractive error may be associated with AMD, although a temporal relationship cannot be determined on the basis of current evidence. | 1 |
Evidence from the current published literature suggested no statistically significant association between Chlamydia pneumoniae infection and AMD. | Evidence from the current published literature suggested statistically significant association between Chlamydia pneumoniae infection and AMD. | -1 |
This meta-analysis suggests that Apo E ε2/ε3/ε4 polymorphisms may not be associated with the risk of POAG. | This meta-analysis suggests that Apo E ε2/ε3/ε4 polymorphisms may be associated with the risk of POAG. | -1 |
This meta-analysis suggests that Apo E ε2/ε3/ε4 polymorphisms may not be associated with the risk of POAG. | There is no evidence that Apo E ε2/ε3/ε4 polymorphisms are associated with the risk of POAG. | 0 |
This meta-analysis suggests that Apo E ε2/ε3/ε4 polymorphisms may not be associated with the risk of POAG. | This meta-analysis suggests that Apo E ε2/ε3/ε4 polymorphisms are associated with the risk of POAG. | 1 |